Abstract:Osteoporosis is a serious health issue among aging postmenopausal women. The majority of postmenopausal women with osteoporosis have bone loss related to estrogen deficiency. The rapid bone loss results from an increase in bone turnover with an imbalance between bone resorption and bone formation. Osteoporosis can also result from excessive glucocorticoid usage, which induces bone demineralization with significant changes of spatial heterogeneities of bone at microscale, indicating potential risk of fracture. This review is a summary of current literature about the molecular mechanisms of actions, the risk factors, and treatment of estrogen deficiency related osteoporosis (EDOP) and glucocorticoid induced osteoporosis (GIOP). Estrogen binds with estrogen receptor to promote the expression of osteoprotegerin (OPG), and to suppress the action of nuclear factor-κβ ligand (RANKL), thus inhibiting osteoclast formation and bone resorptive activity. It can also activate Wnt/β-catenin signaling to increase osteogenesis, and upregulate BMP signaling to promote mesenchymal stem cell differentiation from pre-osteoblasts to osteoblasts, rather than adipocytes. The lack of estrogen will alter the expression of estrogen target genes, increasing the secretion of IL-1, IL-6, and tumor necrosis factor (TNF). On the other hand, excessive glucocorticoids interfere the canonical BMP pathway and inhibit Wnt protein production, causing mesenchymal progenitor cells to differentiate toward adipocytes rather than osteoblasts. It can also increase RANKL/OPG ratio to promote bone resorption by enhancing the maturation and activation of osteoclast. Moreover, excess glucocorticoids are associated with osteoblast and osteocyte apoptosis, resulting in declined bone formation. The main focuses of treatment for EDOP and GIOP are somewhat different. Avoiding excessive glucocorticoid use is mandatory in patients with GIOP. In contrast, appropriate estrogen supplement is deemed the primary treatment for females with EDOP of various causes. Other pharmacological treatments include bisphosphonate, teriparatide, and RANKL inhibitors. Nevertheless, more detailed actions of EDOP and GIOP along with the safety and effectiveness of medications for treating osteoporosis warrant further investigation.

Pathogenesis of glucocorticoid-induced osteoporosis and options for treatment

The epidemiological investigation on glucocorticoid-induced osteoporosis

Update on the Treatment of Glucocorticoid-Induced Osteoporosis

Pathogenic Mechanisms of Glucocorticoid-Induced Osteoporosis

Updates in epidemiology, pathophysiology and management strategies of glucocorticoid-induced osteoporosis

Glucocorticoid Signaling and Bone Biology

Recent advances in the glucocorticoid-induced osteoporosis

Glucocorticoid-Induced Osteoporosis: Increased Awareness as a Management Strategy for Prevention of this Complication in Patients with Systemic Autoimmune Rheumatic Disease

Glucocorticoid-Associated Osteoporosis in Chronic Inflammatory Diseases: Epidemiology, Mechanisms, Diagnosis, and Treatment

When to Start and Stop Bone-Protecting Medication for Preventing Glucocorticoid-Induced Osteoporosis

Glucocorticoid-induced osteonecrosis

Prevention and Treatment of Glucocorticoid-Induced Osteoporosis in Patients with Chronic Kidney Disease

Glucocorticoid-induced autophagy and apoptosis in bone

Glucocorticoids and bone: local effects and systemic implications

Glucocorticoids and osteocyte autophagy

The pathogenesis, diagnosis and clinical manifestations of steroid-induced osteonecrosis

Approach to the Pediatric Patient With Glucocorticoid-Induced Osteoporosis

Osteoporosis Due to Hormone Imbalance: An Overview of the Effects of Estrogen Deficiency and Glucocorticoid Overuse on Bone Turnover

The 2023 Guidelines for the management and treatment of glucocorticoid-induced osteoporosis

Mechanism of glucocorticoid-induced osteoporosis mediated by glucocorticoid receptor

New understanding of pathogenesis of steroid induced osteonecrosis of the femoral head